ArticlePharmacy (Basel, Switzerland)2021
What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review.
Article in Pharmacy (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- "I'm not going to lay back and watch somebody die": a qualitative study of how people who use drugs' naloxone experiences are shaped by rural risk environment and overdose education/naloxone distribution intervention.Harm reduction journal · 2023Trial
- Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff.BMJ open · 2026Article
- Association Between Spinal Manipulative Therapy for Low Back Pain With or Without Sciatica and Opioid Use Disorder: A Retrospective Cohort Study.Health science reports · 2025Article
- Practical naloxone communication tips for pharmacists: Lessons learned from the Linguistic Model of Patient Participation in Care.Research in social & administrative pharmacy : RSAP · 2025Article
- Implementation of harm reduction services for people who use drugs provided by pharmacy staff: a scoping review protocol.BMJ open · 2025Article
- An evidence-based digital prescription opioid safety toolkit for national dissemination: co-design and user testing.Frontiers in digital health · 2025Article
- Adapting the Opening Minds Stigma Scale for Healthcare Providers to Measure Opioid-Related Stigma.Pharmacy (Basel, Switzerland) · 2024Article
- Neighborhood and Individual Disparities in Community-Based Naloxone Access for Opioid Overdose Prevention.Journal of urban health : bulletin of the New York Academy of Medicine · 2024Article
- Take-Home Naloxone Access and Use among Older Adults Living with Pain: A Scoping Review.The Canadian journal of hospital pharmacy · 2024Article
- Exploring the impact of brief training on student pharmacists' naloxone communication skills.PEC innovation · 2023Article
- Organizational Readiness to Implement Community Pharmacy-Based Opioid Counseling and Naloxone Services: A Scoping Review of Current Practice Models and Opportunities.Pharmacy (Basel, Switzerland) · 2023Article
- Considerations for the design of overdose education and naloxone distribution interventions: results of a multi-stakeholder workshop.BMC public health · 2023Article
- Addressing the Opioid Crisis-The Need for a Pain Management Intervention in Community Pharmacies in Canada: A Narrative Review.Pharmacy (Basel, Switzerland) · 2023Review
- Developing a single-session strategy for the implementation of take-home naloxone by community pharmacists using COM-B and design-thinking.Frontiers in health services · 2023Article
- Structural and community changes during COVID-19 and their effects on overdose precursors among rural people who use drugs: a mixed-methods analysis.Addiction science & clinical practice · 2022Article
- Protocol for the Optimizing Naloxone Dispensing in Pharmacies (ONDP) Online Continuing Education Program: A Randomized Controlled Trial.Pharmacy (Basel, Switzerland) · 2022Article
- Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.Drug and alcohol dependence · 2022Article
- Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another.Pharmacy (Basel, Switzerland) · 2021Article
- Access to syringes at pharmacies (ASAP): Preliminary impact of a pharmacy-level intervention.Journal of the American Pharmacists Association : JAPhAArticle
- Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study.Journal of the American Pharmacists Association : JAPhAArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A variety of new sources describing community pharmacy-based take-home naloxone (THN) programs have emerged recently in the literature. There is a need to define the types of take-home naloxone programs being offered to support future research designs in implementing and evaluating standardized programs that fill pharmacist and patient knowledge gaps and lift current barriers for optimal community pharmacy naloxone provision. The objective of this paper is to summarize the literature on community pharmacy-based THN programs, including specific program interventions used to increase naloxone dispensing, naloxone availability and dispensing patterns, facilitators and barriers for the THN programs, and knowledge gaps. Online databases such as PubMed, EMBASE, Scopus, and International Pharmaceutical Abstracts (IPA) and a search of the grey literature were used to identify eligible sources. Sources were screened by two reviewers for eligibility in COVIDENCE software. Both reviewers compared screening results and resolved conflicts through discussion. A data extraction form for all identified full texts was completed by both reviewers and results were compiled through reviewer discussion. Fifty-two sources met the eligibility criteria. The top three barriers identified were: cost/coverage of naloxone, stigma, and education/training for pharmacists. THN program interventions included screening tools, checklists, pocket cards, patient brochures, and utilizing the pharmacy management system to flag eligible patients. Patient knowledge gaps included naloxone misinformation and lack of awareness, while pharmacists demonstrated administrative, clinical, and counselling knowledge gaps. Naloxone availability was found to be highly variable, where independent and rural pharmacies were less likely to stock or dispense naloxone. Further, pharmacies located in districts with higher rates of opioid overdose deaths and lower household income were also less likely to have naloxone available. This review identified multiple new programs, showcasing that the implementation and evaluation of THN programs are an expanding area of research. Future research should focus on implementing and evaluating a THN program through a randomized controlled trial design that incorporates solutions for the barriers and knowledge gaps identified in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.